Harnessing the Immune System in the Battle Against Breast Cancer

Overview

Journal Drugs Context

Specialty Pharmacology

Date 2018 Feb 20

PMID 29456568

Citations 19

Authors

Elizabeth S Nakasone

Sara A Hurvitz

Kelly E McCann

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most prevalent malignancy in women and the second most common cause of cancer-related death worldwide. Despite major innovations in early detection and advanced therapeutics, up to 30% of women with node-negative breast cancer and 70% of women with node-positive breast cancer will develop recurrence. The recognition that breast tumors are infiltrated by a complex array of immune cells that influence their development, progression, and metastasis, as well as their responsiveness to systemic therapies has sparked major interest in the development of immunotherapies. In fact, not only the native host immune system can be altered to promote potent antitumor response, but also its components can be manipulated to generate effective therapeutic strategies. We present here a review of the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.

Citing Articles

Investigating tumor immunogenicity in breast cancer: deciphering the tumor immune response to enhance therapeutic approaches.

Naji O, Ghouzlani A, Rafii S, Sadiqi R, Kone A, Harmak Z Front Immunol. 2024; 15:1399754.

PMID: 39507526 PMC: 11538072. DOI: 10.3389/fimmu.2024.1399754.

Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.

Zaman N, Kushwah A, Badriprasad A, Chakraborty G Int Rev Cell Mol Biol. 2024; 389:257-301.

PMID: 39396849 PMC: 11855062. DOI: 10.1016/bs.ircmb.2024.03.004.

Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar.

Agostinetto E, Curigliano G, Piccart M Cell Rep Med. 2024; 5(6):101575.

PMID: 38759648 PMC: 11228398. DOI: 10.1016/j.xcrm.2024.101575.

Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis.

Zhao J, Liao B, Gong L, Yang H, Li S, Li Y Hum Vaccin Immunother. 2023; 19(2):2254262.

PMID: 37728107 PMC: 10512878. DOI: 10.1080/21645515.2023.2254262.

Targeting triple-negative breast cancer: A clinical perspective.

Popovic L, Matovina-Brko G, Popovic M, Punie K, Cvetanovic A, Lambertini M Oncol Res. 2023; 31(3):221-238.

PMID: 37305385 PMC: 10229315. DOI: 10.32604/or.2023.028525.

References

Coley W . The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991; (262):3-11. View

Yuan Y, Jiang Y, Sun C, Chen Q . Role of the tumor microenvironment in tumor progression and the clinical applications (Review). Oncol Rep. 2016; 35(5):2499-515. DOI: 10.3892/or.2016.4660. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Spaw M, Anant S, Thomas S . Stromal contributions to the carcinogenic process. Mol Carcinog. 2016; 56(4):1199-1213. PMC: 5354948. DOI: 10.1002/mc.22583. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D . Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271(12):907-13. View

Bekaii-Saab T, Roda J, Guenterberg K, Ramaswamy B, Young D, Ferketich A . A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 2009; 8(11):2983-91. PMC: 2996611. DOI: 10.1158/1535-7163.MCT-09-0820. View

Egeblad M, Nakasone E, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18(6):884-901. PMC: 2905377. DOI: 10.1016/j.devcel.2010.05.012. View

Amann M, dArgouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R . Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother. 2009; 32(5):452-64. DOI: 10.1097/CJI.0b013e3181a1c097. View

10.

Liu B, Robinson M, Han Z, Branston R, English C, Reay P . ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003; 10(4):292-303. DOI: 10.1038/sj.gt.3301885. View

11.

BARRERAS L, Vogel C, Koch G, Marcus S . Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic breast cancer. Invest New Drugs. 1988; 6(3):211-5. DOI: 10.1007/BF00175400. View

12.

Gutterman J, Blumenschein G, Alexanian R, Yap H, Buzdar A, Cabanillas F . Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980; 93(3):399-406. DOI: 10.7326/0003-4819-93-3-399. View

13.

Nakasone E, Askautrud H, Kees T, Park J, Plaks V, Ewald A . Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21(4):488-503. PMC: 3332002. DOI: 10.1016/j.ccr.2012.02.017. View

14.

Pecher G, Haring A, Kaiser L, Thiel E . Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002; 51(11-12):669-73. PMC: 11034218. DOI: 10.1007/s00262-002-0317-z. View

15.

Berg J . Inflammation and prognosis in breast cancer; a search for host resistance. Cancer. 1959; 12(4):714-20. DOI: 10.1002/1097-0142(195907/08)12:4<714::aid-cncr2820120414>3.0.co;2-b. View

16.

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

17.

Valedkarimi Z, Nasiri H, Aghebati-Maleki L, Majidi J . Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy. Biomed Pharmacother. 2017; 95:731-742. DOI: 10.1016/j.biopha.2017.07.160. View

18.

Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T . Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. Cancer Sci. 2016; 107(12):1730-1735. PMC: 5198965. DOI: 10.1111/cas.13101. View

19.

Hansen M, Nielsen H, Ditzel H . The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A. 2001; 98(22):12659-64. PMC: 60110. DOI: 10.1073/pnas.171460798. View

20.

Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View